Home
Cancer Vaccines
18 September - 19 September 2013
Cancer Vaccines

SAE Media Group proudly presents the 2nd annual conference on Cancer Vaccines. This year’s event aims to focus on innovation and novel strategies within the field, the regulatory environment, and the future direction of cancer vaccines; as well as offering current preclinical and clinical outlook, data, and case studies.

As cancer is still one of the greatest causes of human mortality it is a very attractive target for vaccination. Despite a dramatic increase in research within cancer vaccines in the last decade, there is still a need for more effective therapies to maximise cancer survival rates. Novel strategies for target selection, vaccine design, immunostimulatory therapies, and other biologics are constantly being developed and improved.

The conference, now in its 2nd year, annual Cancer Vaccine conference will examine not only the current clinical data but also the new innovations within the field. This informative event will draw from expert opinions, groundbreaking data, and regulatory factors to look to the future and assess where the field is advancing. This really is a unique event not to be missed.

FEATURED SPEAKERS

Alex Kudrin

Alex Kudrin

Medical Assessor, Biologicals Licensing, MHRA
Graham Pawelec

Graham Pawelec

Professor of Experimental Immunology, University Of Tuebingen
Martin Glennie

Martin Glennie

Professor of Immunochemistry, University Of Southampton
Oliver Wilbert

Oliver Wilbert

Senior Director Immunotherapies, Merck KGaA
Pierre van der Bruggen

Pierre van der Bruggen

Group Leader, Ludwig Institute for Cancer Research
Rose-Ann Padua

Rose-Ann Padua

Research Director, INSERM
Sonia Quaratino

Sonia Quaratino

Senior Medical Director and Immunology Advisor, Merck Serono

Alex Kudrin

Medical Assessor, Biologicals Licensing, MHRA
Alex Kudrin

Graham Pawelec

Professor of Experimental Immunology, University Of Tuebingen
Graham Pawelec

John Maudsley

CEO, Cancer Vaccines Ltd
John Maudsley

Kevin Pollock

Senior Epidemiologist, NHS National Services Scotland
Kevin Pollock

Kevin Slawin

Executive Chairman & CMO, Bellicum Pharmaceuticals
Kevin Slawin

Liselotte Brix

COO, Immudex
Liselotte Brix

Mark Cobbold

Senior Clinical Research Fellow, University of Birmingham
Mark Cobbold

Martin Glennie

Professor of Immunochemistry, University Of Southampton
Martin Glennie

Oliver Wilbert

Senior Director Immunotherapies, Merck KGaA
Oliver Wilbert

Pierre van der Bruggen

Group Leader, Ludwig Institute for Cancer Research
Pierre van der Bruggen

Ravi Madan

Assistant Clinical Investigator, National Cancer Institute
Ravi Madan

Richard Harrop

Head of Clinical Analysis, Oxford BioMedica (U K) Limited
Richard Harrop

Ronald Rooke

Head of Immunopharmacology, Transgene SA
Ronald Rooke

Rose-Ann Padua

Research Director, INSERM
Rose-Ann Padua

Shao-An Xue

Senior Lecturer, Research Department of Immunology, MBL International Corporation
Shao-An Xue

Sonia Quaratino

Senior Medical Director and Immunology Advisor, Merck Serono
Sonia Quaratino

Søren Jakobsen

Senior Scientist, Immudex
Søren Jakobsen

Conference agenda

clock

13:30

Registration & Coffee

clock

14:00

Welcome & Introduction

clock

14:10

Overview of current immunotherapeutics in development

Ronald Rooke

Ronald Rooke, Head of Immunopharmacology, Transgene SA

Active vs Passive immunotherapy

Targeted pathologies and SOC
Combinations
clock

14:45

Clininal data and predictivity of preclinical models

Ronald Rooke

Ronald Rooke, Head of Immunopharmacology, Transgene SA

Examples of combination therapies

Existing preclinical models
Model optimization
clock

15:40

Afternoon Tea

clock

16:00

Integrating strategies for successful development

Ronald Rooke

Ronald Rooke, Head of Immunopharmacology, Transgene SA

 • Clinical development of combination therapies

clock

17:00

Further Group Discussion

clock

17:30

Close of Workshop

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Oliver Wilbert

Oliver Wilbert, Senior Director Immunotherapies, Merck KGaA

clock

9:10

Advances & Challenges in the Development of Novel Cancer Immunotherapies

Oliver Wilbert

Oliver Wilbert, Senior Director Immunotherapies, Merck KGaA

clock

9:50

An insight on the key results of START, a phase III trial of L-BLP25 (tecemotide) antigen specific immunotherapy

Sonia Quaratino

Sonia Quaratino, Senior Medical Director and Immunology Advisor, Merck Serono

clock

10:30

Morning Coffee

clock

10:50

Accurate and Reliable Immune Monitoring in Cancer Vaccine Development

Søren Jakobsen

Søren Jakobsen, Senior Scientist, Immudex

Proficiency Panel Services

2-dimensional and multiplex MHC multimer analysis
in situ staining of antigen-specific T cells
clock

11:30

Developing antibodies to stimulate anti-cancer immunity

Martin Glennie

Martin Glennie, Professor of Immunochemistry, University Of Southampton

Discuss the nature of anti-cancer immunity and the ability of the immune system to recognise most types of cancer

Explore how antibodies recognising key members of the TNFR superfamily can stimulate T-cell responses against cancer
Show that these immuno stimulating antibodies need to engage Fc receptors in the host to provide sufficient crosslinking of the various TNFRs
Discuss how antibody engineering will be used to optimise crosslinking activity in vivo
clock

12:10

Inducible “Remote Control” Activation of Dendritic Cells

Kevin Slawin

Kevin Slawin, Executive Chairman & CMO, Bellicum Pharmaceuticals

Describe “chemical induction of dimerization (CID)” technology

Describe the use of a CID-controllable CD40-MyD88 activation switch to activate dendritic cells in the correct context
Review results of a Phase I trial of BPX-101, a PSMA-targeted prostate cancer DC vaccine that incorporated a CID-controllable CD40 activation switch
clock

12:50

Networking Lunch

clock

14:10

Improving the clinical efficacy of human cancer vaccines by targeting immune suppression in tumours

Pierre van der Bruggen

Pierre van der Bruggen, Group Leader, Ludwig Institute for Cancer Research

Clinical efficacy of therapeutic cancer vaccines without massive anti-vaccine T cell responses
Current challenges for the clinical efficacy of therapeutic cancer vaccines
Immunosuppression and the resulting impact on cancer vaccines
Soluble galectin antagonists may improve therapeutic vaccine success
 
clock

14:50

Clinical and preclinical aspects of MVA-MUC1-based cancer immunotherapy in NSCLC

Ronald Rooke

Ronald Rooke, Head of Immunopharmacology, Transgene SA

Background

Clinical data

Biomarker identification

Preclinical modelization

clock

15:30

Identification of Biomarkers Predictive of Clinical and Immunological Efficacy in Cancer Patients Treated with TroVax

Richard Harrop

Richard Harrop, Head of Clinical Analysis, Oxford BioMedica (U K) Limited

Cancer vaccines may have a delayed therapeutic effect, thus an early efficacy marker would be valuable

Few immunotherapy compounds have demonstrated a clear link between the predicted mode of action of the product and clinical benefit
Case study data of phase III trial of TroVax in renal cancer patients 
Development of a biomarker using pre-treatment factors which  are readily measured in patients and application to independent dataset comprising patients with renal, colorectal and prostate cancer
clock

16:10

Chairman’s Closing Remarks

clock

16:15

Afternoon Tea

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Sonia Quaratino

Sonia Quaratino, Senior Medical Director and Immunology Advisor, Merck Serono

clock

9:10

Treating Cancer in the Age of Modern Immunotherapy

Ravi Madan

Ravi Madan, Assistant Clinical Investigator, National Cancer Institute

clock

9:50

Manipulating Tumour Immunogenicity in vivo: New Tools for Old Targets

Mark Cobbold

Mark Cobbold, Senior Clinical Research Fellow, University of Birmingham

The talk will describe a new technology to alter the immunogenicity of a tumour in vivo.
Tumour immunogenicity can be manipulated by the delivery of antigens at the tumour site.
The engagement of pre-existing immunity with tumours provides novel mechanism for immunotherapy
Analogous to effective conjugate vaccines
 
clock

10:30

Morning Coffee

clock

10:50

MHC-Peptide Tetramers: Useful tools for optimizing TCR avidity towards tumor antigen peptides in retrovirally transduced T lymphocytes and increasing tumor killing

Shao-An Xue

Shao-An Xue, Senior Lecturer, Research Department of Immunology, MBL International Corporation

Adoptive immunotherapy using TCR gene modified T cells, has not been very successful
TCR constructs, were retrovirally transferred in autologous human T lymphocytes, and tested for cytokine production and tumor killing
T lymphocytes transduced with WT1-TCRs constructs showing a higher tetramer staining had higher production and activity both in vitro and in vivo in mice
MHC- tumor peptide tetramers can be used to select TCR-transduced T lymphocytes with higher tumoricidal activity
 
clock

11:30

Immunological biomarkers predicting survival in late-stage melanoma patients

Graham Pawelec

Graham Pawelec, Professor of Experimental Immunology, University Of Tuebingen

The M category, the presence of NY-ESO-1-reactive T cells and the frequency of CD14+HLA-DR-/low MDSCs in the peripheral blood are associated with survival in late-stage melanoma patients 

Presence of NY-ESO-1-reactive T cells and the M category independently contribute to prognosis of unresectable stage IV melanoma patients
Frequency of MDSCs and the M category independently contribute to prognosis of unresectable stage IV melanoma patients
Frequency of Tregs and presence of Melan A-reactive T cells do not contribute to prognosis of unresectable stage IV melanoma patients
clock

12:10

Networking Lunch

clock

13:30

HPV vaccination programme in Scotland

Kevin Pollock

Kevin Pollock, Senior Epidemiologist, NHS National Services Scotland

High uptake of HPV vaccine in routine cohort(>90%) and catch-up cohort (>65%)
Reduction of high-risk HPV in catch-up cohort
Evaluation of vaccine on cervical cancer precursors (CIN1,2 and 3)
HOPScotch study - HPV oral prevalence in Scotland
clock

14:10

Flipper DNA Vaccine Adjuvant induces immune responses and extends life-span in Mouse Models of acute promyelocytic leukemia and myelodysplastic syndrome

Rose-Ann Padua

Rose-Ann Padua, Research Director, INSERM

DNA vaccination with all-trans retinoic acid induces long term remissions with immune responses in acute promyelocytic leukemia (APL) mice

Novel construct, Flipper, containing additional GC-rich sequences and coding for unique immunogenic peptides was cloned

In normal mice Flipper increased IFNg producing cells in Elispot assays, memory T-cells and MYD88 transcripts

In PML-RARa-mediated APL and NRASD12.BCL-2-mediated MDS mice, extended life-span was observed with immune responses measured and reduction of minimal residual for APL and protein modifications of RAS signaling by NanoPro

 
clock

14:50

Afternoon Tea

clock

15:10

Advances in cellular immunotherapies for cancer

John Maudsley

John Maudsley, CEO, Cancer Vaccines Ltd

Recent advances

Advantages of allogeneic
Markers of safety and efficacy
Future directions
clock

15:50

Global overview of cancer vaccines: Are we moving forward?

Alex Kudrin

Alex Kudrin, Medical Assessor, Biologicals Licensing, MHRA

Why we need cancer immunotherapy and why there is continued interest from the industry and academic communities.
Who are the key players and what is the landscape of the field: products in phase II-III studies.
What is believed to be the new paradigm in cancer immunotherapy. 
Challenges in translating non-clinical data into human models.
Clinical trial design and conduct from both the FDA and EMA perspective. 
The implication of new immunotherapies on health care and reimbursement.
clock

16:30

Chairman’s Closing Remarks and Close of Day Two


Professor of Experimental Immunology
University Of Tuebingen
Professor of Immunochemistry
University Of Southampton
Head of Clinical Analysis
Oxford BioMedica (U K) Limited
Head of Immunopharmacology
Transgene SA
Senior Lecturer, Research Department of Immunology
MBL International Corporation
Senior Scientist
Immudex
Executive Chairman & CMO
Bellicum Pharmaceuticals
Senior Clinical Research Fellow
University of Birmingham
Senior Director Immunotherapies
Merck KGaA
Senior Medical Director and Immunology Advisor
Merck Serono
Senior Epidemiologist
NHS National Services Scotland
Medical Assessor, Biologicals Licensing
MHRA
Research Director
INSERM
CEO
Cancer Vaccines Ltd
COO
Immudex
Group Leader
Ludwig Institute for Cancer Research
Assistant Clinical Investigator
National Cancer Institute

Workshops

Combination Therapies with Immunotherapeutics

Combination Therapies with Immunotherapeutics

Holiday Inn Regents Park
17 September 2013
London, United Kingdom

Holiday Inn Regents Park

Carburton Street
London W1W 5EE
United Kingdom

Holiday Inn Regents Park

Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download

Title


Description

Download

Title


Description


Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

Group Booking

Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SAE Media Group

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smgconferences.com Email: events@saemediagroup.com
Registered in England - SMi Group Ltd trading as SAE Media Group




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SAE Media Group.
Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

Fill in your details to download the brochure

By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.